dimethyl sulfoxide
Autologous stem cell transplantation using high-dose chemotherapy requires the storage of frozen stem cells in liquid nitrogen for their subsequent reinfusion. Prior to storage, dimethyl sulfoxide (DMSO) is added to the cells as a cryoprotectant. Cryoprotectants act by penetrating the cell where they bind to water molecules in solution. This in turn blocks the efflux of water from the cytoplasm during freezing, preventing cellular dehydration or shrinkage and maintaining stable intracellular salt concentrations and pH levels. By slowing the rate of freezing they also prevent the formation of harmful ice crystals within the cell.
DMSO is known to have toxic effects. Animal studies using a swine rete testis model have shown that DMSO exhibits a dose-dependent vasoconstrictor effect.
1,2 Cases of DMSO toxicity have also been reported in humans. This toxicity has been implicated due to the development of acute side effects during the actual reinfusion of cryopreserved cells. General side effects such as nausea, vomiting and abdominal cramps are seen in up to 50% of patients 3 and are believed to arise due to a vagal response caused by the intravenous infusion of a cold liquid. Cardiovascular and respiratory problems such as hypotension and bradycardia 4 or more rarely hypertension and tachycardia, fatal arrythmias, 5 respiratory arrest 6, 7 and diffuse alveolar haemorrhage 8 have been reported. A number of centres have described cases of neurological toxicity such as reversible leukoencephalopathy, 9 epileptic seizures 10,11 and stroke. 12, 13 Elevation of lactate dehydrogenase levels 14 and haemoglobinaemia 15 have also been reported. About 10% DMSO has been used as a standard cryoprotectant in stem cell transplantation. It has been suggested that lowering the dose of DMSO may be advisable. Lower concentrations, for example 5% DMSO 16, 17 or 3.5% DMSO 18 are an effective cryoprotectant. Stem cell washing to remove DMSO appears to have no adverse effect on haematological recovery and may reduce toxicity 19 and fractionation of stem cell administration may similarly reduce side effects. 20 In contrast, it has been hypothesised that DMSO may have beneficial antitumour effects in vivo and that reduction of DMSO dose may be detrimental. 21 It is not known if a reduction in the amount of DMSO infused leads to a reduction in side effects, and there are no current guidelines for its use and most transplant centres are thought to have developed their own protocol for DMSO use and administration. Thus, the aim of this study was to assess current practice in the use of DMSO in EBMT transplant centres and to obtain outline data on its toxicity. would be viewed as a satisfactory response typical for this sort of survey.
Methods
In view of the nature of the survey and the fact that toxic events were not specified in detail, the data have not been subject to extensive statistical analysis.
Results
Replies were received from 97 centres, a response rate of 22%. In all, 95 centres returned completed questionnaires and two centres had not carried out any autologous transplantation. All 95 responders used DMSO as their sole cryoprotectant.
DMSO concentration
Seventy-eight centres used a final concentration of 10% DMSO in the cryopreserved cells and nine centres used 5% DMSO. A concentration of 7.5% DMSO was used by two centres; 20, 8, 7, 6, 5.5 and 2.2% were used by one centre each.
Cell concentration
Sixty one centres limited the frozen cell concentration in the cryopreserved bags. Of these, 23 centres used a limit of 1 Â 10 8 cells/ml and 26 used 2 Â 10 8 cells/ml. Twelve centres used a total of seven other concentrations, 26 centres did not limit cell concentration and there were eight nonresponders.
Forty-one centres used a filter in the infusion line, 29 did not and 20 infused directly using a syringe. Of these, four centres used either a line including a filter or a syringe.
DMSO administration
There was an upper limit in the amount of DMSO given per day used by 57 centres as follows: 80 g (n ¼ 5), 60 g (n ¼ 9), 40 g (n ¼ 12), 20 g (n ¼ 2) and others (n ¼ 29). In the 'others' group there was a total of 14 different limits used, the most frequently cited being 1 g/kg in 13 centres. Of the remainder, 33 centres had no upper limit of DMSO given per day and five centres did not respond.
Further variation was seen in the return of stem cells; 33 preferred to return cells in split doses while 30 did so in single doses and 32 did not respond. Five centres exclusively washed cells before return while 12 did so 'sometimes.' One centre tested for sulphur sensitivity and another specifically questioned recipients regarding a previous history of sulphur allergy.
DMSO toxicity incidence
Of the 95 responding centres, 57 had seen DMSO toxicity (60%). There were at least 470 cases of toxicity reported, although the exact number was difficult to estimate since 11 centres that had experienced DMSO toxicity failed to report the number of cases seen. In total, approximately 34 000 transplants had been carried out by the 95 centres giving a minimum overall incidence (ie the total number of adverse events divided by the total number of transplants performed by all centres) of 1.4%; approximately one in every 70 transplants carried out. The mean incidence per centre of DMSO toxicity was 2.1%.
Effect of DMSO reduction strategies
Use of 10% DMSO (78 centres) was associated with an overall incidence of toxicity of 1.5%, while use of DMSO reduction strategies (concentration o10% or washing of cells before return -22 centres) was associated with an overall toxicity incidence of 0.3%. The effect of different reduction strategies is shown on mean centre incidence of toxicity in Figure 1 .
Nature of DMSO toxicity
A total of 38 centres had seen probable or possible cases of cardiovascular toxicity related to DMSO, while 27 had seen respiratory problems, 12 CNS effects, 11 renal disturbance and 13 others including hepatic dysfunction and anaphylaxis, as detailed in Table 1 . Some patients may have had more than one serious toxicity -this was not specified in the questionnaire.
Discussion
The addition of DMSO to stem cell concentrates is a crucial step in undertaking stem cell transplantation for the vast majority of patients giving time to allow recovery from stem cell mobilisation procedures and possibly further Inspection of the data does suggest that strategies to reduce the amount of DMSO given to patients as part of their stem cell transplant may help to reduce serious toxicity in addition to alleviating 'minor' toxicities of nausea, vomiting, etc. Despite publication of a hypothesis that DMSO might have a role in curing the underlying malignancy in autologous transplantation, 21 there has been no support for this concept. In contrast, the lowest incidence of toxicity was seen in centres that washed cells before transplantation or used lower concentration of DMSO. DMSO toxicity appears to be common and larger transplant centres might expect to see at least one case of severe toxicity every year. The majority of cases are cardiovascular and respiratory in nature. Other effects such as CNS, renal, hepatic and anaphylaxis are less common. As the overall transplant related mortality from autologous procedures falls, the morbidity caused by DMSO takes on increasing importance. From this brief questionnaire we were unable to extract data regarding the severity or mortality related to DMSO but case reports of fatalities do exist. 5 Although the need to protect the viability of the cryopreserved stem cells is paramount it does seem reasonable that strategies to reduce DMSO should be investigated in a prospective manner. We would suggest that the time is right for a more detailed prospective analysis of DMSO toxicity to be undertaken by transplant centres with a view to production of guidelines, which should lead to a fall in the incidence of morbidity and mortality on DMSO administration. Such guidelines should also then set a standard for the introduction of any alternative cryoprotectants, which might be considered for clinical use.
